Staib Ludger, Link Karl Heinz, Blatz Annette, Beger Hans Günther
Department of General and Visceral Surgery, University of Ulm, Steinhövelstrasse 9, 89070 Ulm/Donau, Germany.
World J Surg. 2002 Jan;26(1):59-66. doi: 10.1007/s00268-001-0182-5. Epub 2001 Nov 26.
The objective of this study was to determine surgical morbidity and long-term outcome of colorectal cancer surgery for quality control reasons and as the basis for new treatment modalities. Surgically treated colorectal cancer patients (mean age 65 years) were followed prospectively in a university center (110 months mean follow-up, 1978-1999). Overall survival (OAS), radicality, extent of resection, recurrence, and morbidity were analyzed (log-rank test of survival, multivariate analysis). Altogether, 2452 colorectal cancers localized in the colon (CC, 44.6%), rectum (RC, 44.8%) or multicentric (CRC, 10.6%) were of UICC stages I (19%), II (30%), III (21%), IV (20%), or undetermined (10%). Radicality and stage but not tumor localization influenced the OAS (p <0.0001). The 5-year/10-year OASs were 50%/42% (all), 78%/66% (R0), 46%/36% (R1), 4%/0% (R2), 0% (unresected) and 86%/79% (I), 70%/58% (II), 42%/33% (III), 3%/0% (IV) or 21%/12% (undetermined), respectively (p <0.0001). Multivisceral resections (17%) resulted in morbidity and survival rates equal to those for standard resection. The overall tumor recurrence rate was 27%, mainly with both local and distant relapse (15%). Surgery-related complications occurred in 18% (all), 14% (CC), 21% (RC), or 20% (CRC). The perineal infection rate (RC) was 4%, overall anastomotic leakage 1%, and mortality rate 0.8%. A prospective, uniform follow-up used over two decades warrants quality control in colorectal cancer surgery, which was curative for half of the patients. The morbidity and mortality were low and were not increased by multivisceral resections.
出于质量控制目的并作为新治疗模式的基础,本研究旨在确定结直肠癌手术的手术发病率和长期预后。在一所大学中心对接受手术治疗的结直肠癌患者(平均年龄65岁)进行前瞻性随访(平均随访110个月,1978 - 1999年)。分析总生存率(OAS)、根治性、切除范围、复发情况和发病率(生存率的对数秩检验、多变量分析)。共有2452例结直肠癌,位于结肠(CC,44.6%)、直肠(RC,44.8%)或多中心(CRC,10.6%),国际抗癌联盟(UICC)分期为I期(19%)、II期(30%)、III期(21%)、IV期(20%)或分期未确定(10%)。根治性和分期而非肿瘤位置影响总生存率(p <0.0001)。5年/10年总生存率分别为50%/42%(全部)、78%/66%(R0)、46%/36%(R1)、4%/0%(R2)、0%(未切除)以及86%/79%(I期)、70%/58%(II期)、42%/33%(III期)、3%/0%(IV期)或21%/12%(分期未确定)(p <0.0001)。多脏器切除术(17%)导致的发病率和生存率与标准切除术相当。总体肿瘤复发率为27%,主要为局部和远处复发(15%)。手术相关并发症发生率为18%(全部)、14%(CC)、21%(RC)或20%(CRC)。会阴感染率(RC)为4%,总体吻合口漏发生率为1%,死亡率为0.8%。二十多年来采用的前瞻性、统一随访保证了结直肠癌手术的质量控制,该手术对一半的患者具有治愈性。发病率和死亡率较低,多脏器切除术未使其增加。